Transcription inhibitor actinomycin-D abolishes the cardioprotective effect of ischemic reconditioning

Claudia Strohm1, Miroslav Barancík, Marie von Bruehl

  • 1Department of Experimental Cardiology, Max Planck Institute for Physiological and Clinical Research, Bad Nauheim, Germany.

Abstract

Insights

Actinomycin-D (act-D) abolished ischemic preconditioning (IP)-mediated cardioprotection in pigs by inhibiting transcription factors and mitogen-activated protein kinases (MAPKs). This suggests MAPKs play a transcriptional role in cardioprotection during ischemia.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Ischemic Heart Disease

Background:

  • Mitogen-activated protein kinases (MAPKs) are implicated in cardioprotection.
  • The role of transcriptional events in ischemic preconditioning (IP) is not fully understood.

Purpose of the Study:

  • To investigate the influence of actinomycin-D (act-D), an RNA synthesis inhibitor, on IP-mediated cardioprotection.
  • To determine the effect of act-D on transcription factor levels and MAPK activation in the porcine heart.

Main Methods:

  • Porcine hearts subjected to IP protocol (ischemia/reperfusion).
  • Act-D administered systemically or intramyocardially before or during IP.
  • Infarct size (IS) assessed.
  • Western blot analysis for phosphorylated MAPKs (ERK1/2, SAPK/JNKs) and transcription factors (c-Jun, ATF-2, Elk-1, c-Myc).

Main Results:

  • Systemic act-D abolished IP-induced cardioprotection and significantly increased infarct size.
  • Local act-D reduced IP-mediated cardioprotection in a dose-dependent manner.
  • Act-D inhibited IP-induced phosphorylation of ERK1/2, SAPK/JNKs, and transcription factors, but not the Akt pathway.
  • Act-D inhibited IP-induced S100 protein expression.

Conclusions:

  • Act-D completely abrogated IP-induced cardioprotection in vivo.
  • MAPK signaling pathways (ERK, JNK) appear to exert their cardioprotective effects through transcriptional mechanisms during ischemia and IP.